Industry Research Reports and Market Analysis at MindBranch.com
  

Uniting R&D and Marketing for Integrated Early-Stage Market Preparation (PH100)

Product Type: Market Research Report
Published by: Cutting Edge Information
Published: May 2007
Product Code: R465-61
Description
Bridge the structural, cultural, process and communications gaps between R&D and marketing in early-stage drug development: Early-stage product commercialization continues to challenge even the most skilled and highly respected marketing and drug development organizations. Changing government regulations, pharmacoeconomics, health care practices, and scientific innovations have transformed the drug development landscape in the past decade. As patent protection narrows on many companies’ top-selling brands, the race to market profitable products in record time is intensifying. These transformations have been met concurrently with rising drug development costs and diminishing R&D productivity.

These business drivers require organizational and cultural changes within drug companies in order to unite R&D and marketing - and to direct them toward shared objectives early in development. Injecting market input into drug discovery and early clinical development enables marketing and R&D to focus limited resources on the most promising drug candidates. With market information, R&D can develop drug target libraries and hone in on endpoints with the greatest likelihood of fulfilling unmet medical needs. Ultimately, a continuous exchange of information between R&D and marketing enables companies to make more informed portfolio decisions, to serve their markets better, and to achieve higher profits.

This report covers the critical areas in which R&D and marketing need to work together, including portfolio planning, resource allocation, product hand-offs and ownership, and project and product team structures. Best practices and case studies illustrate numerous tools, tactics, organizational structures and strategies used by top-performing pharmaceutical and biotech companies to bridge the gaps between R&D and marketing in early-stage drug development

Best practices and case studies illustrate a variety of tools, tactics, organizational structures and strategies used by top-performing pharmaceutical and biotech companies to bridge the gaps between R&D and marketing in early-stage drug development. This report covers all the critical areas in which R&D and marketing need to work together, including portfolio planning, resource allocation, product hand-offs and ownership, and project and product team structures.
Table of Contents

Case Studies and Business Practices:

The following case studies and best practices are included in the report:



Portfolio Planning & Resource Allocation:


How resource allocation processes come to exist in drug companies

Resource allocation process differences between business unit/franchise and matrixed organizations

Connecting portfolio review to long-term commercial resource allocation planning

Case Study: Company J emphasizes cross-functional input to build a comprehensive view of all development projects

Case Study: Company H’s high-level, cross-functional portfolio review/steering committee conducts annual portfolio assessments

Case Study: Company F performs quarterly portfolio assessments but sets marketing budgets annually

Risk assessments engender objectivity in marketing resource allocation planning

Strategies for winning resources to support early-stage commercialization

Bridging the Culture Gap to Unite R&D and Marketing


Blending marketing insights with discovery and development

Assigning a marketing manager to the development team

Assembling and integrated early-stage commercial development team

Strengthening the global R&D-marketing interface

Overcoming the R&D-marketing cultural gap

Incorporating market research and competitive intelligence in clinical trial planning and label development

Transitioning product ownership from R&D to marketing

Structural Integration of R&D and Marketing


Early-stage marketing organizational structure

Case Study: Company A coordinates early marketing activities through marketing sub-teams

Early-stage product development and commercialization: Evolving from project management to product marketing teams

Phase 1: The trial management team forms to oversee clinical trials and marketing

Phase 2: The emergence of the product marketing team

Phase 3: Commercial strategic sub-teams form to complete tactical transition from R&D to marketing

Coordinating among multiple functions on project management teams

Case Study: Company D empowers the project management function to coordinate pre-launch commercial development activities

Case Study: Company B manages project team personnel transitions

Case Study: Company E balances matrixed project management team with dedicated resources

Early-stage commercialization activities

Case Study: Company A’s phase-by-phase marketing activities for the early development stages

Strategies, tools and tactics for cross-functional coordination of early-stage commercialization activities

Case Study: Company B leverages its matrixed structure for functional expertise

Case Study: Company E builds knowledge-sharing centers of excellence

Case Study: Company B utilizes a common language to facilitate cross-functional communication

Case Studies: Companies use IT tools to inject competitive intelligence into marketing and R&D collaborations

Communication is the key to coordination in early development

Case Study: Company C gathers input from support functions to inform early commercial team decisions

Case Study: Company G engages key players to identify market needs and characteristics

Stage-gate decision making process

Case Study: Company C’s stage-gate decision-making process



Ordering and More Information
Price and Delivery Options



MindBranch has been the leading provider of industry and investment research from more than 550 independent research firms since 1992. With over 90,000 market research reports, MindBranch is your trusted source of competitive business intelligence.